A new initiative has been launched in the UK to investigate reports of severe side effects linked to popular weight loss medications, following a significant number of individuals experiencing issues related to the pancreas. The study, coordinated by the Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with Genomics England, seeks to identify whether genetic predispositions play a role in adverse reactions to these drugs.
Injections for weight management, including popular brands like Mounjaro, Ozempic, and Wegovy, have gained traction as aids for tackling obesity and type 2 diabetes. Nonetheless, health authorities are currently investigating incidents of both acute and chronic pancreatitis among consumers. Although a concrete association between the drugs and these medical cases has yet to be confirmed, the number of reports has led to a more thorough inquiry.
The MHRA is encouraging individuals aged 18 and older who have been hospitalized with pancreatitis while using these medications to report their experiences via the Yellow Card system—an online platform that allows the public and healthcare professionals to flag potential safety concerns related to medical products. Participants will be invited to join a broader study to assess whether genetic factors may influence how individuals respond to the treatment.
As an element of the investigative procedure, chosen participants will be requested to offer more health details and a saliva specimen. This is intended to investigate possible genetic indicators that might forecast an individual’s likelihood of experiencing pancreatitis or other severe adverse effects from medications for weight reduction. The primary aim of the study is to enhance the safety of these treatments by customizing prescriptions according to a person’s genetic characteristics.
Dr. Alison Cave, head of safety at the MHRA, stressed the significance of this study in averting potential risks. She pointed out that gaining insights into the genetic foundations of negative drug responses could greatly improve the security of medical interventions in the UK. “Around a third of severe medication side effects might be preventable with genetic testing,” she remarked, underscoring the wider impact on the healthcare sector.
Financially, the impact of adverse drug reactions is substantial. Hospitalizations related to complications from medications are estimated to cost the NHS over £2.2 billion annually. Reducing these events through better prediction and prevention could free up valuable resources and improve patient outcomes across the board.
Interest in GLP-1 receptor agonists such as Ozempic and Wegovy has surged, primarily because of their success in weight management and controlling blood sugar levels. These medications operate by emulating hormones that control hunger and insulin secretion, proving valuable not just for weight reduction but also for managing glycemic levels in individuals with diabetes. Nonetheless, the swift increase in their use has raised concerns regarding their safety, particularly when utilized without medical oversight.
In addition to gastrointestinal symptoms commonly reported—such as nausea, constipation, and diarrhoea—more serious complications like pancreatitis have been documented. According to MHRA data, up until mid-May this year, ten reported deaths involved individuals who were using these medications and later developed pancreatitis. The exact cause of these outcomes remains uncertain, as additional health factors could have contributed.
The study also aims to account for the rising use of these medications through unofficial channels. Many individuals now obtain weight loss drugs online without a prescription, bypassing essential medical guidance. This unregulated access increases the risk of misuse, inappropriate dosing, and lack of monitoring for side effects, further complicating the picture for health regulators.
Adding more layers of complexity, the MHRA recently released a caution concerning possible interactions between Mounjaro and oral birth control methods. Initial findings indicate that the contraceptive pills’ effectiveness might be diminished in certain patients on Mounjaro, creating further worries for those dependent on hormonal contraceptive methods.
Professor Matt Brown, the head of scientific operations at Genomics England, emphasized the advantages of healthcare guided by genetic data. He mentioned that despite the effectiveness of medications such as Ozempic and Wegovy, all drugs have a potential for side effects. The aim of genomic studies is to identify patients who are more at risk and tailor treatment plans to suit them better.
He described the long-term vision as moving toward more personalized medical care—where prescriptions are tailored not just to a diagnosis, but to a patient’s unique genetic makeup. Such an approach could revolutionize treatment protocols, reduce the frequency of adverse reactions, and promote a preventive rather than reactive model in healthcare.
Este estudio representa un avance en ese ámbito. Al recopilar datos de los pacientes y analizar factores genéticos, el MHRA y Genomics England planean establecer una base más sólida para métodos más seguros de prescripción de medicamentos. Los resultados podrían tener amplias repercusiones, no solo para las personas que actualmente utilizan medicamentos para perder peso, sino también para el desarrollo futuro de fármacos y las medidas reglamentarias en diversos campos médicos.
In the meantime, healthcare officials highlight that weight loss injections are not a universal solution for obesity. Although they can be effective when given correctly and monitored by a physician, there are possible risks. Individuals should consult healthcare professionals before starting these treatments and promptly inform them of any unusual symptoms they encounter.
The results of the current research may provide better understanding on the optimal use of these medications while reducing risks. If it proves successful, it might result in the incorporation of genetic screening into the prescribing procedures for weight loss medications, ensuring treatments are both safe and effective for each person.
.jpg "Centro de lactancia en Guatemala")
